Search for other works by this author on:
Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. ( Cometta, A., Calandra, T., Gaya, H., Zinner, S. H., de Bock, R., del Favero, A. Addition of a glycopeptide should be considered only in patients at high risk of Gram-positive infection. J Antimicrob Chemother 1995; 35: 1–5Afzal-Shah M, Livermore DM. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. The characteristics of 76 assessable febrile episodes (39 with meropenem … The treatment was considered a failure if (i) fever (>38.5°C) persisted for longer than 48 h in steps 1 and 2 (in step 2 in the meropenem arm irrespective of whether or not teicoplanin was added) and longer than 96 h in step 3 or with modified therapy, (ii) the patient died of a cause related to the primary infection within the first 48 h (steps 1 and 2) to 96 h (step 3) of the treatment, (iii) the patient showed clinical deterioration with or without persistence of the primary isolated microorganism or detection of a new bacterial pathogen other than the primary one. Meropenem was well tolerated, with no reports of nausea or toxicity to the central nervous system. Empirical treatment of fever in neutropenic children: the role of the carbapenems. Antimicrob Agents Chemother 1995 Feb; 39: 445–52Cometta A, Calandra T, Gaya H, et al. 1A: 17–20Leyland MJ, Bayston KF, Cohen J, et al. J Clin Oncol 1992 Feb; 10(2): 316–22Klastersky J. The most frequently documented infections in both arms were bacteraemias (22.1 versus 26.5%), predominantly caused by Gram-positive organisms (57.9 versus 71.1%). 30-day mortality was 12% (23/187) in piperacillin-tazobactam group vs. 4% (7/191) in the meropenem group (p= 0.002 with fragility index of five). An antipseudomonal β-lactam agent plus an aminoglycoside, 2 β-lactam agents or monotherapy with an appropriate cephalosporin or carbapenem are all currently recommended as first-line empirical treatment in this patient group by the Infectious Diseases Society of America. Arch Intern Med 1992 Feb; 152: 283–91Freifeld AG, Walsh T, Marshall D, et al. The overall evaluation was performed 7 days after the completion of treatment. Therapy-induced alterations in host defense in children receiving therapy for cancer. Eur J Cancer 1995 Nov; 31A: 2013–22Klastersky J. Drugs 1994; 47(3): 506–35Jones RN, Pfaller MA. Eighty (53%) episodes initially treated with ceftazidime and 63 (41%) episodes treated with meropenem were considered to have failed treatment because it was thought necessary to administer additional antibacterial agents; however, modifications were made twice as often because of fever that persisted beyond 2-3 days than because of obvious causes of failure such as persistent infection.
[email protected] INTRODUCTION: Chemotherapy related neutropenia developing in oncologic … eCollection 2018 Aug 20.Ferdosian F, Ghiliyan R, Hashemi A, Akhondzadeh B, Gholampoor E.Iran J Ped Hematol Oncol. Drug-induced neutropenia and agranulocytosis will be reviewed here. Bacterial resistance: a worldwide problem. & Tutschka, P. J. Ann Hematol 1998 Feb; 76: 73–80de la Cámara R, Figuera A, Sureda A, et al. 2nd ed. D: 13–24Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. It may be possible to discharge selected patients at low risk of complications on oral or parenteral outpatient therapy.Meropenem, a parenteral carbapenem, has excellent activity against all Gram-negative and Gram-positive anaerobic pathogens, and slightly more variable activity against Gram-positive aerobic organisms. Intent-to-treat analysis of outcome of all eligible episodes ( Intent-to-treat analysis of outcome of all eligible episodes ( Multivariate analysis of prognostic factors for successful response to monotherapy at 48 h of all eligible episodes ( Multivariate analysis of prognostic factors for successful response to monotherapy at 48 h of all eligible episodes (Corresponding author. Others causes of acquired neutropenia, such as primary immune mechanisms, chemotherapy, and infections, as well as congenital neutropenia in children are discussed separately. Search for other works by this author on: